Fortress Biotech And Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
FBIO•Crystalys Therapeutics raises $130 million in Series B
- Fortress Biotech Inc and subsidiary Urica Therapeutics announced Crystalys Therapeutics’ $130 million Series B financing.
July 27 (Reuters) - Fortress Biotech Inc FBIO.O:
- FORTRESS BIOTECH AND SUBSIDIARY URICA THERAPEUTICS ANNOUNCE CRYSTALYS THERAPEUTICS’ $130 MILLION SERIES B FINANCING
Source text: ID:nGNX3bFqdJ
Further company coverage: FBIO.O
